RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 41 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 41

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院GuangzhouHospital page
  2. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  3. Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
  4. Study siteAffiliated Hospital of Xuzhou Medical University徐州医科大学附属医院XuzhouHospital page
  5. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  6. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  7. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  8. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  9. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  10. Study siteFirst Affiliated Hospital of Soochow University苏州大学附属第一医院SuzhouHospital page
  11. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  12. Study siteFirst Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院)HefeiHospital page
  13. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  14. Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
  15. Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  16. Study siteFirst Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院HangzhouHospital page
  17. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  18. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  19. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  20. Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
  21. Study siteGeneral Hospital of Ningxia Medical University宁夏医科大学总医院YinchuanHospital page
  22. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  23. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  24. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  25. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  26. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  27. Study siteNanfang Hospital南方医科大学南方医院GuangzhouHospital page
  28. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  29. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  30. Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
  31. Study siteSecond Hospital of Hebei Medical University河北医科大学第二医院ShijiazhuangHospital page
  32. Study siteSecond Xiangya Hospital中南大学湘雅二医院ChangshaHospital page
  33. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  34. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  35. Study siteSichuan Cancer Hospital四川省肿瘤医院ChengduHospital page
  36. Study siteTianjin Chest Hospital天津市胸科医院TianjinHospital page
  37. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  38. Study siteXiangya Hospital中南大学湘雅医院ChangshaHospital page
  39. Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
  40. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
  41. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05990127, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer [AJCC] 8th edition).

    Inclusion criterion 5

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 3

  4. Histologically confirmed small cell lung cancer (SCLC).

    Exclusion criterion 1

    Active malignant tumors within the past 5 years, except for tumors in this study and scured local tumors.

    Exclusion criterion 5

    Known medical history of immunodeficiency or positive HIV test.

    Exclusion criterion 12

  5. Pregnant or lactating women.

    Exclusion criterion 6

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05990127, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The subjects voluntarily participated in the study with full informed consent and signed written informed consent form.
  • Aged ≥18 years when the subject signed the informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy ≥ 3 months.
  • Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) that not amenable to complete surgical resection and not amenable to radical concurrent/sequential chemoradiation or metastatic (Stage IV) NSCLC (American Joint Committee on Cancer [AJCC] 8th edition).
  • No prior systemic therapy for advanced or metastatic NSCLC was received.
  • PD-L1 TPS < 1%.
  • No EGFR sensitive mutations or ALK gene translocation alterations.

Exclusion Criteria:

  • Histologically confirmed small cell lung cancer (SCLC).
  • NSCLC with driver gene mutations for approved targeted drug indications.
  • Active central nervous system (CNS) metastases were present.
  • Pulmonary radiation therapy > 30 Gy within 6 months prior to first dose.
  • Active malignant tumors within the past 5 years, except for tumors in this study and scured local tumors.
  • Pregnant or lactating women.
  • Clinically significant cardiovascular or cerebrovascular disease.
  • Subjects with a known history of severe hypersensitivity to other monoclonal antibodies. A known history of allergy or hypersensitivity to all investigational drugs or any of their components.
  • Active autoimmune disease requiring systemic treatment within 2 years prior to the start of study treatment, or autoimmune diseases that may relapse or require scheduled treatment as judged by the Investigator.
  • Known active pulmonary tuberculosis.
  • Patients with active hepatitis B or active hepatitis C.
  • Known medical history of immunodeficiency or positive HIV test.

Quoted from ClinicalTrials.gov, NCT05990127, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05990127, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05990127